Study of Lurbinectedin in Pediatric and Young Adult Patients With Relapsed/Refractory Ewing Sarcoma
Phase: Recruiting
First Posted: July
Condition(s): Ewing Sarcoma, Solid Tumors
NCT Number: NCT05734066 Other Study ID Number(s): JZP712-101
What Is the Purpose of This Study?
This study is conducted in two phases.
- The phase 1 portion of the study evaluates the safety, tolerability, pharmacokinetics (PK), recommended phase 2 dose (RP2D), and effectiveness of lurbinectedin monotherapy in pediatric participants with previously treated solid tumors.
- This is followed by the phase 2 portion, to further assess the effectiveness and safety in pediatric and young adult participants with recurrent/refractory Ewing sarcoma.
Who Can Take Part in This Study?
- Patients with a confirmed solid tumor.
What Will Happen During This Study?
- Participants will receive Lurbinectedin as intravenous infusion once every three weeks.
Principal Investigator
Discover More Research
Explore additional studies relating to sarcoma and solid tumorsYour Might Also Be Interested In
Exploring Pediatric Clinical Research
Clinical research involves the study of people, data or tissue samples to understand children’s health and diseases. It’s the foundation for medical advancement and plays a large role in improving health outcomes for children, teenagers and families.
Clinical Research: How We Keep Volunteers Safe
Clinical research is a type of research that involves people. Research participants help researchers to study new types of treatments, like new medicines or medical devices. It might even include changes in how people live or act, such as different ways to eat or exercise.
Stay Updated With Clinical Research. Follow @NCHClinicalResearch on Instagram!
Parents and caregivers can learn more about clinical research on our Instagram channel, @NCHClinicalResearch. You can be part of the clinical research that moves us forward in our journey to best outcomes for all children, everywhere.